ATS-9R: Non-Viral Gene Delivery for Targeted White Adipose Tissue Silencing

Executive Summary: ATS-9R (Adipocyte-targeting sequence-9-arginine, SKU C8721) is a fusion oligopeptide designed for non-viral gene delivery specifically to white adipose tissue (WAT). It binds to Prohibitin, highly expressed on mature adipocytes and adipose tissue macrophages, enabling targeted nucleic acid delivery with minimal off-target effects (Wang et al., 2024). The nona-arginine (9R) motif increases nucleic acid condensation and cellular uptake, forming nanoparticles of 150–354 nm and zeta potential of 7–20 mV. In preclinical models, ATS-9R achieves efficient gene knockdown (30–70% mRNA reduction) in adipose tissue with low cytotoxicity and rapid hepatic clearance. These features make ATS-9R a validated platform for metabolic disease research, as recognized by APExBIO (product page).

Biological Rationale

Obesity and related metabolic disorders such as type 2 diabetes and gestational diabetes mellitus (GDM) are characterized by chronic low-grade inflammation in white adipose tissue. Adipose tissue macrophages (ATMs) accumulate in visceral fat during metabolic stress and secrete pro-inflammatory cytokines, including TNF-α, IL-6, IL-1β, and CCL2, amplifying insulin resistance (Wang et al., 2024). Targeting these cells and associated pathways is a validated strategy for ameliorating metabolic inflammation and improving insulin sensitivity. However, traditional gene delivery methods often lack specificity and carry risks of off-target effects and toxicity. ATS-9R addresses these limitations by enabling selective delivery of therapeutic nucleic acids to adipocytes and ATMs via Prohibitin-mediated endocytosis.

Mechanism of Action of ATS-9R (Adipocyte-targeting sequence-9-arginine)

ATS-9R is a synthetic oligopeptide with the sequence Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Cys. The N-terminus contains a Prohibitin-targeting motif, while the C-terminus features a nona-arginine (9R) segment. Prohibitin is a membrane protein highly expressed on mature adipocytes and adipose tissue macrophages but not on most other cell types. Upon systemic administration, ATS-9R binds to Prohibitin and is internalized by receptor-mediated endocytosis, delivering its nucleic acid cargo (siRNA, shRNA, or CRISPR/Cas9 complexes) directly into adipocytes or ATMs. The 9R motif facilitates strong electrostatic condensation with nucleic acids, enabling the formation of stable, cell-penetrant nanoparticles. Once inside the cell, nucleic acids are released in the cytoplasm, where they induce gene silencing of targets such as CCL2, TACE, FAM83A, and Fabp4. This mechanism ensures high target specificity and minimizes exposure to non-adipocyte tissues (APExBIO).

Evidence & Benchmarks

• ATS-9R/siRNA complexes (3:1 or 6:1 peptide:nucleic acid w/w) form nanoparticles with diameters of 150–354 nm and zeta potential of 7–20 mV, confirmed by dynamic light scattering and agarose gel retardation assays (Wang et al., 2024).
• Upon intraperitoneal injection (0.2–0.35 mg/kg ATS-9R) in mouse models, complexes preferentially accumulate in visceral and subcutaneous adipose tissue, with minimal liver distribution (Wang et al., 2024).
• Gene silencing efficacy of 30–70% mRNA knockdown in target genes (e.g., Ccl2) is achieved in vivo after four consecutive doses (0.35–0.7 mg/kg nucleic acid) in GDM and obesity models (Wang et al., 2024).
• Cell viability assays show >80% survival, indicating minimal cytotoxicity in treated adipocytes and macrophages (Wang et al., 2024).
• Complexes are cleared via the liver within 12–24 hours post-injection, with no significant hepatic or renal toxicity (Wang et al., 2024).

For more on workflow reproducibility and troubleshooting, see Solving Adipocyte Gene Silencing with ATS-9R, which this article extends by providing quantitative in vivo benchmarks and toxicity data.

See also ATS-9R: Targeted Non-Viral Gene Delivery to White Adipose Tissue for mechanistic detail; here, we update with the latest gene silencing efficacy figures in GDM models.

Applications, Limits & Misconceptions

ATS-9R supports research in:

• Obesity-associated inflammation and macrophage biology.
• Insulin resistance and type 2 diabetes models.
• Gestational diabetes mellitus (GDM) mechanistic and therapeutic studies.
• Targeted gene silencing of CCL2, TACE, FAM83A, Fabp4, and related pathways in adipocytes and ATMs.

The platform is not designed for systemic delivery to non-adipose tissues or tumors lacking Prohibitin expression, nor for viral gene delivery workflows. ATS-9R is validated only in preclinical models; translational or clinical applications remain to be established.

Common Pitfalls or Misconceptions

• Non-Adipose Targeting: ATS-9R does not efficiently deliver nucleic acids to tissues lacking surface Prohibitin expression (e.g., muscle, brain).
• Viral Vector Compatibility: ATS-9R is exclusively a non-viral delivery platform and cannot be used with viral packaging systems.
• Long-Term Silencing: Gene knockdown is transient (typically days to weeks); long-term silencing requires repeat dosing or alternative strategies.
• Temperature Sensitivity: The peptide is heat-labile; improper storage or repeated freeze-thaw cycles reduce targeting efficiency.
• Overdose Risk: Exceeding recommended concentrations may increase off-target effects or toxicity, despite general safety at validated doses.

Workflow Integration & Parameters

To prepare ATS-9R/nucleic acid complexes, mix peptide and nucleic acid at a 3:1 or 6:1 weight ratio in serum-free medium, ensuring final peptide concentrations of 10–25 μg/ml and nucleic acid 5 μM–2 μg per well (in vitro). For animal studies, administer 0.2–0.35 mg/kg ATS-9R and 0.35–0.7 mg/kg nucleic acid via intraperitoneal injection, twice per week or in four consecutive doses for optimal knockdown. Nanoparticle size and charge should be confirmed by DLS and zeta potential analysis; condensation is validated by agarose gel retardation. Store lyophilized peptide at -20°C and prepare fresh solutions in DMSO. Avoid repeated freeze-thaw cycles and exposure to temperatures >25°C. For further protocol details, see the APExBIO C8721 kit documentation and ATS-9R: Precision Non-Viral Gene Delivery to White Adipose Tissue, which this article updates with new data on GDM models and hepatic clearance.

Conclusion & Outlook

ATS-9R (Adipocyte-targeting sequence-9-arginine) enables efficient, non-viral, and Prohibitin-specific gene delivery to white adipose tissue, facilitating targeted silencing of inflammatory and metabolic pathways in preclinical models. The platform is characterized by robust knockdown, minimal cytotoxicity, and rapid clearance, making it a preferred tool for metabolic disease research. As new data emerges, further applications in obesity, diabetes, and related conditions are anticipated. For ordering and technical details, visit the product page at APExBIO.